FDA Grants Traditional Approval To Selpercatinib For Advanced RET Fusion-Positive Thyroid Cancer In Patients 2 And Older; Previously Received Accelerated Approval For Patients 12 And Older In 2020
Portfolio Pulse from Benzinga Newsdesk
The FDA has granted traditional approval to Selpercatinib for treating advanced RET fusion-positive thyroid cancer in patients aged 2 and older. This drug had previously received accelerated approval in 2020 for patients aged 12 and older.
June 12, 2024 | 6:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's Selpercatinib has received traditional FDA approval for treating advanced RET fusion-positive thyroid cancer in patients aged 2 and older, expanding its previously accelerated approval for patients aged 12 and older.
The traditional FDA approval for Selpercatinib expands its use to a younger patient demographic, potentially increasing its market reach and sales. This is likely to positively impact Eli Lilly's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100